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[18F]FDG PET is a well-established method for the evaluation
of patients with suspected Alzheimer’s disease (AD) and other
neurodegenerative diseases [1]. This tool has the unique abil-
ity to estimate the local cerebral metabolic rate of glucose
consumption (CMRgl), thus providing information on the dis-
tribution of neuronal death and synapse dysfunction in vivo
[2]. Clinically, [18F]FDG PET plays a major role in the early
and differential diagnosis of dementia due to AD by showing
specific disease patterns of hypometabolism, reflecting neuro-
nal dysfunction in affected brain regions even in the earliest
stages of the disease [1]. However, the role of [18F]FDG PET
in identifying patients affected by AD but who are still at the
stage of mild cognitive impairment (MCI) is less established.
Although various studies have indicated a high predictive val-
ue in this population, appropriate standardization approaches
(i.e. semiquantification methods, observer-independent analy-
ses, identification of cut-off values) and the value of [18F]FDG
PET in comparison to amyloidosis biomarkers are still a mat-
ter of debate.
Recently, a Cochrane review was published with the objec-
tive of determining the diagnostic accuracy of [18F]FDG PET
for identifying subjects with MCI who will clinically convert
to AD or other dementias [3]. The authors concluded that there
is no evidence supporting routine clinical use of [18F]FDG
PET to identify those patients with MCI who will develop
AD. For several reasons, we do not agree with the authors of
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this Cochrane review that existing data on the value of FDG
PET in MCI supports such a categorical conclusion. Indeed,
clear variability in diagnostic performance of [18F]FDG PET
is found in the literature, as correctly reported in the Cochrane
review. This variability, however, is not exclusively attribut-
able to the method itself, but rather can be explained by a
number of factors concerning study design, definitions of
MCI itself and data analysis procedures.
We would like to highlight some of these factors in greater
detail, because we believe that knowledge on these issues may
be necessary to correctly interpret the available literature and
to appreciate the diagnostic value of [18F]FDG PET in MCI.
Methodology
Cochrane reviews are internationally recognized systematic
reviews that provide a standard for evidence-based healthcare.
The Cochrane review on brain [18F]FDG PET included
longitudinal cohort studies published between 1999 and
2013 in which MCI patients underwent an [18F]FDG PET
scan at baseline and were followed-up clinically to assess
whether there was conversion to dementia. These studies were
selected through an extensive search of electronic databases
and by checking the reference lists of relevant studies (for
details see Smailagic et al. [3]). Patients included in this re-
view fulfilled specific inclusion criteria. In particular, MCI
patients were included (1) according to the clinical criteria
defined by Petersen et al. [4] and Winblad et al. [5], (2) if they
presented with a Clinical Dementia Rating scale score of 0.5
[6], or (3) if they met one of the other 16 descriptions of MCI
discussed by Matthews et al. [7]. This rather ‘inclusive’ ap-
proach reflects the fact that the definition of MCI is quite
diverse across the literature of the last 10 years.
Patients with isolated memory impairment, such as those
included by Berent et al. [8], are not easily comparable with
those who fulfil current MCI criteria. In contrast to dementia
based on AD, MCI is not a homogeneous diagnostic entity.
This inhomogeneity also applies to the cohorts of MCI pa-
tients finally included in the Cochrane review. Therefore, it
is questionable whether a meta-analysis of results obtained
from a series of highly heterogeneous MCI samples allows
any conclusion about the diagnostic method itself. The ob-
served variability in the results obtained with [18F]FDG in
MCI may indeed reflect heterogeneity in the patient samples
rather than variability in diagnostic performance.
The studies included, by necessity, employed delayed ver-
ification of conversion to dementia and the diagnosis of prob-
able AD was based on NINCDS-ADRDA guidelines [9] and
confirmed by exclusion of other causes of dementia through
clinical, paraclinical and neuropsychological criteria. The time
between [18F]FDG PET and verification of conversion was
considered appropriate (low risk of bias) when the duration
of follow-up was longer than 1 year. However, as the authors
of the Cochrane review state themselves, the duration of
follow-up is quite critical, as sufficient time is needed to cap-
ture the natural course of progression. A patient who still has
Bstable^ MCI after 1 year may still convert to AD after 2 or
3 years [10]. In this respect, it should be noted that it is hard to
say whether positive [18F]FDG PET findings in patients with
clinically stableMCI should be considered false-positive if the
follow-up time is less than 3 years [11, 12]. In our view, it
would be important to define a target conversion time win-
dow. This is indeed a relevant topic, partly investigated by
Cabral et al. [11]. Their results clearly show that (using a
specific machine learning approach) the sensitivity for detec-
tion critically increases during the last 12 months prior to
conversion. Specific investigations on this topic are thus re-
quired in order to specify the time frame in which the
[18F]FDG PET results should be considered valid and to de-
fine guidelines for repeating the diagnostic test.
Finally, 16 studies were selected, consisting of a total of
697 subjects, and all studies were evaluated for methodolog-
ical quality. From amethodological point of view, both studies
with qualitative and those with semiquantitive analyses of
[18F]FDG PET scans were included in the Cochrane review.
Sensitivity analysis, however, was performed only in 14 stud-
ies (150 subjects) as three studies included patients from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
and only the largest one of these studies was included in the
analysis [13]. In contrast, no threshold concerning the number
of subjects included in a study was set and actually 6 out of 16
of the studies included had fewer than 30 subjects. The rela-
tively low sample size of some of the studies included may
also account for part of the results. In fact, smaller studies are
often associated with larger effect sizes, which could be a
reflection of ‘small study bias’ (i.e. the possibility that the
available evidence is biased) [14].
Results of the Cochrane review
Sensitivity and specificity values varied widely and ranged
from 25 % to 100 % for sensitivity and from 15 % to 100 %
for specificity. However, both these values were higher than
80 % in about half of the studies included [15–20], an accu-
racy that compares better with previous studies in which con-
firmation of underlying neurodegenerative pathology was ob-
tained at autopsy. In the latter case, [18F]FDG PET identified
patients with ADwith a sensitivity of 94% and a specificity of
73 % [21]. In addition, it has to be noted that sensitivity and
specificity values at the lower end of the range given above
were derived (1) from studies performed using stand-alone
PET scanners with poorer sensitivity and lower spatial resolu-
tion than available PET/CT scanners, and/or (2) using a very
small group of oncological patients without evidence of brain
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lesions as controls [22, 23]. All these limitations were clearly
discussed by the original authors and these articles represent a
proof of past efforts to develop and define the specific pattern
of AD at the stage of MCI. Nevertheless, these challenges are
now overcome by the availability of both freeware software
and officially certified observer-independent analysis tools of-
fered by several vendors allowing comparison with age-
matched control databases.
The highly heterogeneous [18F]FDG PET sensitivity and
specificity results highlighted in the Cochrane review might
also be explained by different criteria and differences in meth-
odological approaches between studies, e.g. regarding criteria
for [18F]FDG positivity. In fact, in only ten studies were PET
analyses based on a combination of visual qualitative and
semiquantitative analyses performed. In addition, different
thresholds, different brain regions as well as different scaling
procedures were used to assess positivity. Actually, the sensi-
tivity and specificity of [18F]FDG PET (as well as of all AD
biomarkers) depend largely on the method of interpretation,
resulting in improved diagnostic and prognostic accuracy with
software-aided reading [24]. In summary, we do not agree
with the view of the authors of the Cochrane review that the
variability in diagnostic performance represents the main lim-
itation in the use of [18F]FDG PET in clinical practice. In our
opinion, this heterogeneity is rather a reflection of the exten-
sive work that is ongoing to compare and validate analytical
tools for guiding interpretation of [18F]FDG PET data within
the heterogeneous MCI population.
New data and perspectives
Smailagic et al. searched PubMed and other databases up to
January 2013. However, this is a rapidly evolving field and
many other studies have been published since then, showing
the strong effort of the nuclear medicine community to assess
the relevance of cerebral [18F]FDG PET for the early diagno-
sis of dementia. On 1 March 2015, another 17 papers on this
topic, published between January 2013 and February 2015,
could be identified [11, 25–40]. In addition, two other papers,
published in 2012 and investigating the diagnostic role of
[18F]FDG PET in MCI, were not identified by the authors of
the Cochrane review [41, 42]. Three of these 19 studies used a
normal reference population as the source of normative data,
an approach that was not considered in the Cochrane review
[38, 39, 41]. The median sensitivity and specificity of these
more recent studies were 80 % and 72.5 %, respectively.
A systematic review of the results obtained in these studies
is beyond the scope of this editorial: we summarize here only
some of the more relevant results and trends emerging from
this recent literature.
Firstly, the number of subjects included in these more re-
cent studies is much higher than the number incorporated in
the Cochrane reviewwith only one study including fewer than
30 subjects [26], suggesting that the use of [18F]FDG PET for
early detection of dementia is increasingly being used, and
larger series are available for assessing its value. In order to
achieve these large sample sizes, a synergistic effort across
memory clinics and countries is in place. The vast majority
of studies use data from multicentre projects, not only from
the ADNI (dataset used in nine of the previously mentioned
studies), but also from the Network for Standardisation of
Dementia Diagnosis (NEST-DD) and the European
Alzheimer’s Disease Consortium (EADC) PET project. In-
deed, multicentre databases, and in particular the openly avail-
able ADNI data, are an ideal testing set for new analytical
approaches.
Secondly, all studies published recently used a semiquan-
titative approach, such as regional uptake or statistical analysis
using a reference control group, confirming that the nuclear
medicine community is ready for systematic addition of ob-
jective approaches to the traditional approach of visual rating.
Among these semiquantitative approaches, two main catego-
ries can be identified, namely univariate and multivariate tests.
Although it can be expected that multivariate approaches may
be able to capture the biological complexity better, validation
for broad clinical application of tools based on multivariate
approaches is still lacking. In contrast, this is available for
several univariate methods [43, 44]. Within this context, it is
important to note that eight of the studies published during the
last 2 years specifically tested Bready to use^ tools for single
subject analysis, thus providing estimates of performance that
can be expected in daily routine [28, 30, 35–38, 40, 41].
Thirdly, four of the recent papers did not just study
[18F]FDG PET, but also measured its added value within the
overall diagnostic framework when other information (clini-
cal, genetic profile, amyloid positivity) were taken into ac-
count, showing that [18F]FDG PET positivity significantly
modifies the risk of progression, both in amyloid-positive
and in amyloid-negative patients [27, 28, 31, 35]. This is in-
deed a more natural approach, trying to simulate clinical prac-
tice and integrating different AD biomarkers, balancing
healthcare costs with diagnostic accuracy. Within this frame-
work, in a recent survey assessing the perceived usefulness of
AD biomarkers for the aetiological diagnosis of MCI, neurol-
ogists working in EADC centres agreed that only a combina-
tion of amyloidosis and neuronal injury biomarkers (such as
[18F]FDG PET) is a strong indicator of an AD signature [45].
This position is also in line with published guidelines explic-
itly requiring the presence of neuronal injury markers to come
to a conclusion of Bintermediate probability^ or Bhigh proba-
bility^MCI/AD [46]. Furthermore, recently the validity of this
approach has been further confirmed by a large retrospective
multicentre study showing that, in the clinical setting, the
combined use of both amyloid and neuronal injury markers
offers the most accurate prognosis in MCI patients [47].
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Conclusions
Based on a large body of evidence on its diagnostic sensitivity
for the identification of AD, in 2004 [18F]FDG PET imaging
was approved by the Centers for Medicare and Medicaid Ser-
vices (CMS, USA) as a routine examination tool for early and
differential diagnosis of AD. Since then, large amounts of
additional [18F]FDG PET data have become available show-
ing that the addition of [18F]FDG PET to clinical examina-
tions increases diagnostic accuracy in identifying AD patients
even in the predementia stage. Of course, new opportunities
and new challenges are coming up, which require the defini-
tion of the specific role of [18F]FDG PET in the era of AD
biomarkers (i.e. relationship with other biomarkers and role as
a marker of progression in AD [46, 48]). Meanwhile, in daily
clinical practice, nuclear medicine experts should continue to
perform high-quality [18F]FDG PET scans, constantly im-
proving the standard through continuous education and the
use of appropriate tools, knowing that it is one of the most
informative biomarkers currently available for the prediction
of dementia at the MCI stage.
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